I wouldn't say a worse deal. In fact I think th
Post# of 30067
(Total Views: 383)
Posted On: 04/01/2022 3:49:09 AM
I wouldn't say a worse deal.
In fact I think the opposite. Not just to take an opposing pov, but because the percentage of the company they got was worth the gamble for Gerald.
I see it as Long v. Short term bet.
Short term bet is for Dr. Arad
Long term bet better for Gerald & Todos.
Short play is more of the Company which Gerald sees as cost saving verse the Long term play of paying a royalty in perpetuity.
Give up less than 10% more of the Company and still have majority control and voting sounds to me a better position than having to pay a single digit royalty for the life of the company.
Single digit was what was in the original framework of the deal.
I would think the best comparison to the deal in term of a Single Digit would be the CATK deal which was the being of the relationship/ deal.
NOTE 5 - INVESTMENT IN AFFILIATD COMPANIES, NET (CONT.)
B. Antigen COVID Test Killer (Cont.)
7. Distribution rights
The Company will have Covid Nutraceutical distribution rights worldwide except for Israel according to the following terms:
A. CATK will receive royalties fee in a rate of 8% (“Royalty”) from the net sales of every nutraceutical product sold whether it was sold directly or by the Company of through the Company’s agent
I'd say another bonus is, it makes for a far cleaner amd less convoluted company should a buyout occur.
And if it's Todos that buys them out as as they have it as a possibility, they still have the option of throwing in a royalty down the road rather than having to increase a royalty payment.
I personally like this deal more. But everyone will see it differently.
And if this is valuation Breakdown is even remotely close both companies will do just fine!
But think of what that royalty payment would be!
Valuing the Deal
A rough estimate of a drug’s value can be done using a peak sales multiple. Typically in late stages of development with promising candidates, to obtain valuations, peak sales multiples can be at least 2-4x. It is not out of the realm of possibilities for Todos’ Tollovir to beat Gilead’s remdesivir in peak sales since the drug, by currently available data, is much more effective.
Therefore, it's reasonable to think Todos might generate at least $6 billion in sales of Tollovir. A 3x multiple on this peak sales number will yield $18 billion in valuation; $10.8 billion of value to Todos. The company is currently trading at a ~$25 million market capitalization. Even when investors factor in risk and required clinical development, there is a large disconnect between $10.8 billion and $25 million. This is important because Paxlovid is in scarce supply and other antivirals will be needed, even molnupiravir.
Tollovid sales, the cousin nutraceutical of Tollovir, is a revenue driver for 3CL Pharma subsidiary as well as Todos. Todos recently sponsored a Superbowl Celebrity Flag Football event that was broadcasted to over 30 million households.
This event marks the beginning of a robust marketing campaign that can amplify Tollovir sales and potentially put the company in a place where they don’t need to raise capital. Additionally, Tollovid and TolloTest bring additional value to the company.https://www.benzinga.com/general/biotech/22/03/26164823/todos-medical-acquires-lucrative-nlc-assets-for-pennies-on-the-dollar
After the numbers today, I see why Gerald's said that he
esees the value “Starting with a B not an M.”
And last, this was thrown in there too.
Additionally, the assets include new intellectual property that covers follow-on products based on Tollovir, including new chemical entity (NCE) therapeutic candidates.
In fact I think the opposite. Not just to take an opposing pov, but because the percentage of the company they got was worth the gamble for Gerald.
I see it as Long v. Short term bet.
Short term bet is for Dr. Arad
Long term bet better for Gerald & Todos.
Short play is more of the Company which Gerald sees as cost saving verse the Long term play of paying a royalty in perpetuity.
Give up less than 10% more of the Company and still have majority control and voting sounds to me a better position than having to pay a single digit royalty for the life of the company.
Single digit was what was in the original framework of the deal.
I would think the best comparison to the deal in term of a Single Digit would be the CATK deal which was the being of the relationship/ deal.
NOTE 5 - INVESTMENT IN AFFILIATD COMPANIES, NET (CONT.)
B. Antigen COVID Test Killer (Cont.)
7. Distribution rights
The Company will have Covid Nutraceutical distribution rights worldwide except for Israel according to the following terms:
A. CATK will receive royalties fee in a rate of 8% (“Royalty”) from the net sales of every nutraceutical product sold whether it was sold directly or by the Company of through the Company’s agent
I'd say another bonus is, it makes for a far cleaner amd less convoluted company should a buyout occur.
And if it's Todos that buys them out as as they have it as a possibility, they still have the option of throwing in a royalty down the road rather than having to increase a royalty payment.
I personally like this deal more. But everyone will see it differently.
And if this is valuation Breakdown is even remotely close both companies will do just fine!
But think of what that royalty payment would be!
Valuing the Deal
A rough estimate of a drug’s value can be done using a peak sales multiple. Typically in late stages of development with promising candidates, to obtain valuations, peak sales multiples can be at least 2-4x. It is not out of the realm of possibilities for Todos’ Tollovir to beat Gilead’s remdesivir in peak sales since the drug, by currently available data, is much more effective.
Therefore, it's reasonable to think Todos might generate at least $6 billion in sales of Tollovir. A 3x multiple on this peak sales number will yield $18 billion in valuation; $10.8 billion of value to Todos. The company is currently trading at a ~$25 million market capitalization. Even when investors factor in risk and required clinical development, there is a large disconnect between $10.8 billion and $25 million. This is important because Paxlovid is in scarce supply and other antivirals will be needed, even molnupiravir.
Tollovid sales, the cousin nutraceutical of Tollovir, is a revenue driver for 3CL Pharma subsidiary as well as Todos. Todos recently sponsored a Superbowl Celebrity Flag Football event that was broadcasted to over 30 million households.
This event marks the beginning of a robust marketing campaign that can amplify Tollovir sales and potentially put the company in a place where they don’t need to raise capital. Additionally, Tollovid and TolloTest bring additional value to the company.https://www.benzinga.com/general/biotech/22/03/26164823/todos-medical-acquires-lucrative-nlc-assets-for-pennies-on-the-dollar
After the numbers today, I see why Gerald's said that he
esees the value “Starting with a B not an M.”
And last, this was thrown in there too.
Additionally, the assets include new intellectual property that covers follow-on products based on Tollovir, including new chemical entity (NCE) therapeutic candidates.
(0)
(0)